A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis by Sven Mahner et al.
ORIGINAL PAPER
A prospective multicenter study of treosulfan in elderly patients
with recurrent ovarian cancer: results of a planned safety analysis
Sven Mahner • Gu¨lten Oskay-O¨zcelik • Elke Heidrich-Lorsbach •
Stefan Fuxius • Harald Sommer • Peter Klare • Antje Belau • Birgit Ruhmland •
Thomas Heuser • Heinz Ko¨lbl • Susanne Markmann • Jalid Sehouli
Received: 26 January 2012 / Accepted: 29 March 2012 / Published online: 15 April 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Background Treosulfan, an alkylating agent, has
demonstrated activity in recurrent ovarian carcinoma. It is
equieffective as oral (p.o.) and intravenous (i.v.) formula-
tion. To explore the preference and compliance of elderly
patients regarding p.o. or i.v. treosulfan for the treatment of
relapsed ovarian carcinoma, women aged 65 years or older
were included in this prospective multicenter study. Since
elderly patients usually have several concomitant diseases
and experience more treatment toxicity, an interim safety
analysis was planned and performed after 25 patients
finished therapy to assess the tolerability of the treatment
regimens.
Methods Patients had a free choice of treosulfan i.v.
(7,000 mg/m2 day 1 of a 28-day cycle) or p.o. (600 mg/m2
day 1–28 of a 56-day cycle) for a maximum of 12 cycles
(i.v.) or 12 months (p.o.). Indecisive patients were ran-
domized. Toxicity was evaluated according to the NCI-
CTC version 2.0.
Results Twenty-five of 51 recruited patients completed
therapy at the time of the planned interim analysis (median
age, 75 years; range, 70–82). Median ECOG was 1, and
median number of prior chemotherapy regimens was 2. A
median number of 4 cycles (range, 1–12) were administered
per patient. Anemia was the most common hematological
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toxicity (88 % of patients). Most frequent non-hemato-
logical toxicities were nausea (76 %), constipation (68 %),
and fatigue (64 %).
Conclusion Treatment was generally well tolerated
despite the fact that most patients suffered from multiple
comorbidities and were heavily pretreated. There were no
unexpected hematological or non-hematological toxicities.
Based on this safety analysis, the next step of study
recruitment was continued.
Keywords Ovarian cancer  Elderly  Chemotherapy 
Patient preference  Safety  Treosulfan
Abbreviations
ADL Activities of daily living
iADL Instrumental activities of daily living (after
Lawton and Brody)
ICH International Conference on Harmonisation of
technical requirements for registration of
pharmaceuticals for human use
GCP Good clinical practice
i.v. Intravenous
p.o. Per oral
SAE Serious adverse event
Introduction
In Europe, 58 % of all cancers occur in women older than
65 years with a peak in the 7th and 8th decade (Pignata and
Vermorken 2004). Median age at diagnosis of ovarian
cancer is 63 years (Altekruse et al. 2010). As the propor-
tion of older adults in the population is growing, the
number of women with ovarian cancer is expected to
increase worldwide. Irrespective of these facts, older
women are underrepresented in clinical trials, mainly due
to the common misbelieve that elderly patients would not
tolerate treatment toxicities. Restrictive inclusion criteria
regarding age, adequate hematological, renal, and cardiac
functions lead to non-enrollment of elderly patients in
clinical trials (Harter et al. 2005). However, previous
research could demonstrate that the decision to treat elderly
patients with chemotherapy should be based on patients’
functional age rather than chronical age (Pallis et al. 2010a,
b). Therefore, our trial also included a multidimensional
geriatric assessment of each enrolled patient.
Treosulfan is the prodrug of a bifunctional alkylating
cytostatic agent that is active in ovarian carcinoma and
other solid tumors (Gropp et al. 1998; Ko¨pf-Maier and Sass
1996). It can be administered oral or as intravenous infu-
sion (Hilger et al. 2000) and is known for its relatively low
hematological and non-hematological toxicity.
In the present study, women with relapsed ovarian
cancer aged 65 years or older were enrolled after failure of
platinum-containing therapy. Patients had free choice
between treosulfan p.o. and i.v. Since elderly patients
usually suffer from several concomitant diseases and
experience more treatment toxicity, an interim safety
analysis was planned and performed after 25 patients fin-
ished therapy to assess the safety and tolerability of the
treatment regimens.
Patients and methods
This open-label multicenter phase-IIIb trial was conducted
at 47 German institutions; the first 25 patients analyzed in
this safety analysis were recruited in 10 centers.
Primary aim of the study was to explore the preference
and compliance of elderly patients for p.o. or i.v. treosul-
fan. Toxicities, progression-free survival, overall survival,
geriatric assessment (iADL—instrumental activities of
daily living and ADL scale), and quality of life were
defined as secondary objectives. Toxicity analysis focused
on hematological toxicities as well as on number of
patients with treatment delay or discontinuation. There
were no predefined toxicity limits specified in the study
protocol concerning continuation of the study, which was
subject to regular review of the data safety monitoring
board.
The study was performed according to ICH-GCP
(International Conference on Harmonisation-Good Clinical
Practice) guidelines. An independent monitoring institute
was responsible for data control (Alcedis GmbH, Giessen,
Germany). Approval from local ethical committees was
gained at every participating center, and written informed
consent was provided by each participant.
Patients with histologically confirmed recurrent ovarian
cancer having received at least one prior platinum-based
cancer therapy were allocated to this trial. The number of
prior therapies was initially planned as 1 and subsequently
changed by amendment to at least 2 previous therapies
after 7 patients had been included. The amendment was
implemented to reflect the new treatment standards of
topotecan or liposomal doxorubicin as treatment of choice
for platinum-resistant ovarian cancer at second line.
Minimal age for inclusion was 65 years with no upper
limit. Eligible patients were required to have a life expec-
tancy of more than 3 months, and an Eastern Cooperative
Oncology Group (ECOG) performance status less than 3.
Two-dimensional measurement of the tumor or, alterna-
tively, increase in CA125 values greater than 100 U/ml were
necessary.
Serum creatinine levels and total bilirubin had to be
below 1.25 times the upper limit of normal, in case of liver
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metastases bilirubin was allowed to be up to 5 times upper
limit of normal. Adequate bone marrow function as indi-
cated by a leukocyte count greater than 2,000/ll and
platelet count greater than 100,000/ll was required.
Patients suffering from secondary malignancies that
influenced the prognosis were not eligible. Current treat-
ment with any chemo-, immuno-, or hormonal therapy as
well as previous treatment with treosulfan was additional
exclusion criterion.
Before start of therapy, registered patients could choose
between oral and intravenous treosulfan. Indecisive women
were randomized to one of the treatment arms. The patients’
preference regarding the way of application will be part of
the final analysis of this trial. Oral medication was given as
600 mg/m2 treosulfan on day 1–28 of a 56-day cycle.
In the i.v. group, patients received 7,000 mg/m2 over
15–30 min on day 1 of a 28-day cycle. No general pre-
medication was defined, and participating centers could
apply their specific standards. Primary supportive admin-
istration of granulocyte-colony-stimulating factor (G-CSF)
was allowed. Concomitant use of food, especially milk,
was recommended for all women receiving treosulfan as
oral application.
To account for the limited hematopoietic resources of
elderly patients, chemotherapy was applied only if leuko-
cyte count was C3.5 9 109/l and platelet count was greater
than 100 9 109/l.
Dose reductions were applied in case of severe throm-
bocytopenia or leucopenia. No re-escalation of a reduced
dose was allowed. Progress of the tumor, intolerable grade
3 or 4 toxicities (excluding nausea grade 3), and/or a
treatment delay exceeding more than 2 weeks lead to dis-
continuation of treatment.
Blood samples for hematology (hemoglobin, leukocytes,
and platelets) and blood chemistry (creatinine, alkaline
phosphatase, SGOT, SGPT, gamma-GT, LDH, total bili-
rubin, albumin, and total serum protein) as well as CA-125
were collected prior to each cycle.
Toxicity was graded according to the classification of
the National Cancer Institute ‘‘Common Terminology
Criteria for Adverse Events’’ (CTCAE) in the version of
1999 (version 2.0) at the end of every cycle. Safety was
assessed by the analysis of toxicity parameters (occurrence
of adverse events, serious adverse events, and deaths).
The EORTC QLQ-OV-28-questionnaire was used to
assess the quality of life. Patients were asked to fill in the
questionnaire before start of therapy, during and at the end
of treatment. Comorbidity was determined according to the
‘‘Cumulative Illness Rating Scale’’ at the beginning and
the end of study therapy. For the geriatric assessment, the
Scales of Lawton and Brody were used. Patients were
asked for self-concept regarding the instrumental activities
of daily living at registration, during therapy and at the end
of study treatment. If a patient reached \8 points in the
iADL, the Barthel ADL Index was used additionally.
Results
This safety analysis was performed after 25 patients with
recurrent ovarian cancer were included in this study and
finished treatment. Baseline characteristics are shown in
Table 1. Median age was 75 years (range, 70–82). The
majority of patients had advanced stage disease (FIGO
III/IV) at initial diagnosis. Forty-four percent of the
patients had a recurrence-free interval after primary ther-
apy of more than 12 months. All patients had prior surgery
and a median of 2 chemotherapies. Eight patients (32 %)
underwent second-line and seven patients (28 %) third-line
therapy. Two patients had more than 4 recurrences before
inclusion into the study. Two patients had received hor-
mone therapy before inclusion. Distant metastases were
rare and localized to the liver or lung. Nineteen patients
had an ECOG performance status of 0 or 1, and six patients
had an ECOG of 2.
The median number of concomitant diseases was 5, with
a range from 1 to 9, mostly cardiovascular or orthopedic
(Table 2).
The majority of the patients (n = 23) decided on the
application form, 2 patients were indecisive and allocated
to a treatment arm by randomization. Altogether 22
patients (2 by randomization) received i.v. application, and
3 patients decided to take treosulfan orally. Patients
received a median of 4 cycles of study medication (range,
1–12). The median scheduled dose per cycle of 7,000
mg/m2 (i.v.) and 600 mg/m2 (p.o.) per day could be applied
(Table 3). Median total cumulative dose of the p.o.-patients
was 70,000 mg, whereas patients getting the i.v. applica-
tion had a median total cumulative dose of 49,840 mg.
With oral therapy, no dose reductions were necessary,
whereas two patients in the i.v. therapy arm received 9
cycles (8.3 %) with reduced treosulfan dose. Overall, 17 %
of cycles were delayed. One woman received the maximum
planned number of 12 cycles, 24 patients stopped therapy
early. The reasons for therapy discontinuation are shown in
Table 4. In most cases, the reason was progressive disease
(48 %). Two patients died during the study period.
All non-hematological and hematological toxicities
occurring during therapy are shown in Tables 5 and 6. The
majority of all documented toxicities were of grade 1 or 2.
Nausea and constipation were the most frequently recorded
non-hematological toxicities. Altogether 21 non-hemato-
logical toxicities of grade 3 and 1 non-hematological
toxicity (neuropathy) of grade 4 occurred (Table 5).
The most common hematological toxicities were leu-
copenia and neutropenia. Leucopenia of grade 3 occurred
J Cancer Res Clin Oncol (2012) 138:1413–1419 1415
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in 3 patients (12 %) and 1 woman each (4 %) suffered
from neutropenia of grade 3 or 4 (Table 6).
Altogether 16 serious adverse events (SAE) were doc-
umented for nine patients. The predominant reason for
SAE-reporting was hospitalization (14 reports). Death was
the matter for the remaining 2 SAEs. An additional patient
was hospitalized due to progressive disease and died in
Table 1 Patient characteristics
No. of patients in study 51
No. assessed for toxicity 25
Median age, in years (range) 75 (70–82)
ECOGa
0 2 (8.0 %)
1 17 (68.0 %)
2 6 (24.0 %)
FIGO-stage at initial diagnosis
IIA 2 (8.0 %)
IIC 1 (4.0 %)
IIIA 1 (4.0 %)
IIIB 2 (8.0 %)
IIIC 15 (60.0 %)
IV 4 (16.0 %)
Grading at initial diagnosis
G2 10 (40.0 %)
G3 11 (44.0 %)
GX 4 (16.0 %)
Histology at initial diagnosis
Serous papillary 19 (76 %)
Others or NOS 6 (24 %)
Relapse-free interval after primary therapy
\6 months 5 (20.0 %)
6–12 months 9 (36.0 %)
[12 months 11 (44.0 %)
Previous therapies
Surgery 25 (100.0 %)
Radiotherapy 0 (0.0 %)
Chemotherapy 25 (10.0 %)
Number of previous chemotherapies,
median (range)
2 (1–6)
1 6 (24.0 %)
2 8 (32.0 %)
3 7 (28.0 %)
4 2 (8.0 %)
5 1 (4.0 %)
6 1 (4.0 %)
Hormone therapy 2 (8.0 %)
Therapy situation at study entry
1st relapse 7 (28.0 %)
2nd relapse 9 (36.0 %)
3rd relapse 5 (20.0 %)
4th relapse 1 (4.0 %)
[4th relapse 3 (12.0 %)
Location of distant metastases
Liver 6 (24.0 %)
Lung 2 (8.0 %)
Concomitant diseases, median number (range) 5 (1–9)
a Eastern Cooperative Oncology Group Performance Score
Table 2 Concomitant diseases
Site n % (n = 122)
Blood pressure 18 14.8
Musculoskeletal system 18 14.8
Heart 13 10.7
Lower gastrointestinal tract 11 9.0
Blood vessels 10 8.2
Neurological disease 9 7.4
Metabolism and endocrine system 8 6.6
Respiratory system 9 7.4
Liver 7 5.7
Kidney 7 5.7
Upper gastrointestinal tract 6 4.9
Urinary tract 3 2.5
Psychiatric 3 2.5
122 100.0
Table 3 Treatment delivery
Total cycles (patients) 117 (25)
Cycles per patient, median (range) 4 (1–12)
Cycles with treosulfan i.v. (patients) 108 (22)
Cycles with treosulfan p.o. (patients) 9 (3)
Treosulfan dose i.v. (mg/m2), median (range) 7,000 (4,060–7,000)
Treosulfan dose p.o. (mg/m2) per day,
median (range)
600 (600–600)
Dose reduction i.v., cycles/patients 9 (8.3 %)/2 (8.0 %)
Dose reduction p.o., cycles/patients 0 (0 %)/0 (0 %)
Cycles delayed (p.o. and i.v.) 20 (17 %)
Table 4 Reasons for early therapy discontinuation [less than 12
cycles (i.v.) or 12 months of therapy (p.o.)]






Progressive disease 12 48.0
Patients choice 3 12.0
Other reasons 3 12.0
Death 2 8.0
Hematological toxicity of grade 3 or 4 2 8.0
Non-hematological toxicity of grade 3 or 4 1 4.0
Relevant concomitant disease 1 4.0
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Table 5 Non-hematological toxicities: highest grade per patient (in alphabetic order)










Patients (%) Patients (%) Patients (%) Patients (%) Patients (%)
Abdominal pain or convulsion 5 (20.0 %) 3 (12.0 %) 1 (4.0 %) 9
Acute viral rhinopharyngitis 1 (4.0 %) 1
Alopecia 4 (16.0 %) 1 (4.0 %) 2 (8.0 %) 7
Amnesia 1 (4.0 %) 1
Anorexia 3 (12.0 %) 1 (4.0 %) 4
Arthralgia 1 (4.0 %) 3 (12.0 %) 4
Arthritis 1 (4.0 %) 1 (4.0 %) 2
Ascites 1 (4.0 %) 1
Back pain 2 (8.0 %) 2
Chest pain (not cardial and not pleuritic) 1 (4.0 %) 1 (4.0 %) 2
Common cold 1 (4.0 %) 1 (4.0 %) 2
Conjunctivitis 1 (4.0 %) 1 (4.0 %) 2
Constipation 7 (28.0 %) 5 (20.0 %) 2 (8.0 %) 3 (12.0 %) 17
Diaphoresis 1 (4.0 %) 1
Diarrhea 1 (4.0 %) 1 (4.0 %) 1 (4.0 %) 3 (12.0 %) 6
Dyspnea 2 (8.0 %) 2 (8.0 %) 4
Dysuria 1 (4.0 %) 1
Edema 2 (8.0 %) 2 (8.0 %) 4
Fatigue 12 (48.0 %) 2 (8.0 %) 2 (8.0 %) 16
Gastritis 1 (4.0 %) 1
Headache 2 (8.0 %) 2
Hearloss 1 (4.0 %) 1
Hemorrhage 1 (4.0 %) 1
Hoarseness 2 (8.0 %) 2
Hydronephrosis 1 (4.0 %) 1
Hydronephrosis 1 (4.0 %) 1
Hyperkalemia 1 (4.0 %) 1
Hypoglycemia 1 (4.0 %) 1
Hypotension 1 (4.0 %) 1
Ileus 2 (8.0 %) 2
Incontinence 1 (4.0 %) 1
Infection without neutropenia 1 (4.0 %) 1 (4.0 %) 2
Insomnia 1 (4.0 %) 1
Myalgia 1 (4.0 %) 1 (4.0 %) 2
Nausea 12 (48.0 %) 5 (20.0 %) 1 (4.0 %) 2 (8.0 %) 20
Pain (bone) 3 (12.0 %) 2 (8.0 %) 5
Peripheral arterial occlusive disease 1 (4.0 %) 1
Peripheral neuropathy 8 (32.0 %) 3 (12.0 %) 1 (4.0 %) 12
Pruritus 1 (4.0 %) 1
Pyrexia (without neutropenia) 1 (4.0 %) 1 (4.0 %) 2
Skin-related toxicities 7 (28.0 %) 2 (8.0 %) 3 (12.0 %) 12
Sleep disorder 1 (4.0 %) 1 (4.0 %) 2
Stomatitis/pharyngitis 5 (20.0 %) 1 (4.0 %) 6
Subileus 1 (4.0 %) 1
Vertigo 2 (8.0 %) 1 (4.0 %) 3
Vomiting 7 (28.0 %) 5 (20.0 %) 1 (4.0 %) 2 (8.0 %) 15
Weight loss 1 (4.0 %) 1
Xerostomia 3 (12.0 %) 3
Sum of events 102 51 21 1 15 190
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hospital. In all 3 cases, death was concerned as not related
to study medication and progress of the underlying
malignant tumor was stated as cause of death.
Discussion
Ovarian cancer has the highest incidence in the seventh and
eighth decades of life (Gondos et al. 2007; Oleitan et al.
2000). Due to substantial improvements in surgery and
chemotherapy regimens for ovarian cancer, longer survival
results in increasing number of older patients with recur-
rent disease. These elderly women are usually less ‘‘fit’’
than younger patients and therefore require specific (mono)
therapies with moderate side effects. Combination thera-
pies tend to be more toxic than monotherapies, especially
with respect to myelotoxicity (Breidenbach et al. 2003).
The current standard therapy for platinum-sensitive
recurrent ovarian cancer (progress 6 months or later after
the end of previous therapy) is platinum-based combina-
tions with liposomal doxorubicin, gemcitabine, or paclit-
axel (Pujade-Lauraine et al. 2010) and in case of
contraindications for platinum the combination of trabect-
edin and liposomal doxorubicin (Monk et al. 2010). All
these combination have a relatively high hematological or
non-hematological toxicity in common. For patients with
disease recurrence within 6 months (so-called platinum
resistance), monotherapies with topotecan, liposomal
doxorubicin, paclitaxel, or gemcitabine represent the cur-
rent standard approach. Again, all three have distinct
hematological and non-hematological toxicity (Uziely
et al. 1994; Meier et al. 2009; Sehouli et al. 2008). The use
of anthracyclines, which are among the most active single
agents for the treatment of recurrent ovarian cancer, is
often limited in elderly patients due to the high prevalence
of cardiac comorbidity.
The management of recurrent ovarian cancer in elderly
women remains to be a clinical challenge. The main goals of
treatment strategies are to maintain tumor control and quality
of life as long as possible drugs of low toxicity. The alkylating
agent treosulfan has previously shown activity as mono-
therapy against recurrent ovarian cancer exhibiting only mild
toxicities (Reed et al. 2006; Keldsen et al. 1998). In several
European countries, it is approved for palliative therapy alone
or in combination in women with advanced ovarian cancer
after failure of platinum-containing therapies, and we present
the results of the safety analysis of the first prospective study
regarding tolerability of palliative chemotherapy in elderly
patients with relapsed ovarian cancer.
In a clinical phase-III trial with platinum-refractory
ovarian cancer comparing topotecan versus treosulfan, it
was demonstrated before that hematological toxicity was
significantly less frequent in the treosulfan arm, whereas
non-hematological toxicity was similar in both arms (Meier
et al. 2009). Stratification according to platinum sensitivity
revealed for the stratum ‘‘relapse time up to 6 months after
primary chemotherapy’’ that both treatments were equally
effective with regard to overall survival, while progression-
free survival was favorable in the topotecan arm.
Median age of the patients in the topotecan and treo-
sulfan arm was 58 (range, 30–78) and 59 (27–77) years,
respectively, whereas patients in this current study had a
median age of 75 years. In contrast to most published
series where patients had only one prior chemotherapy
(usually platinum/paclitaxel), patients in our study had a
median of 2 prior chemotherapies. At study entry, there
were 9 patients (36 %) in second relapse and 5 patients
(20 %) in third relapse. Three patients (12 %) even had
more than 4 prior relapses. Most of the subjects suffered
from concomitant cardiovascular disease and orthopedic
problems. In median, 5 concomitant diseases were present.
Mostly, the concomitant diseases were classified as mild or
moderate; in 15 cases, the grading was severe. The higher
number of concomitant disease in elderly patient usually
goes along with more concomitant medication. Since the
concomitant medication also impose distinct toxicity and
side effects, it is important to use chemotherapy, which
exerts only moderate toxicity in this context. The patients
analyzed here took a median of 4 concomitant medications
at the time of registration. Comorbidity and co-medication
thus directly influence efficacy and tolerability of chemo-
therapy, and the choice of therapeutic regimens therefore
has to carefully balance risks and potential benefits.
In the current study, most of the observed hematological
and non-hematological toxicities were of grade 1 or 2.
Therapy with treosulfan is well tolerated in this patient
Table 6 Hematological toxicities: highest grade per patient
Hematological toxicities Grade 1 (n = 25) Grade 2 (n = 25) Grade 3 (n = 25) Grade 4 (n = 25) Grade unknown (n = 25)
Patients (%) Patients (%) Patients (%) Patients (%) Patients (%)
Anemia 9 (36.0 %) 8 (32.0 %) 1 (4.0 %) 4 (16.0 %) 22
Leukopenia 8 (32.0 %) 1 (4.0 %) 3 (12.0 %) 5 (20.0 %) 17
Neutropenia 1 (4.0 %) 1 (4.0 %) 1 (4.0 %) 6 (4.0 %) 9
Thrombocytopenia 10 (40.0 %) 1 (4.0 %) 1 (4.0 %) 4 (16.0 %) 16
Sum of events 28 10 6 1 19 64
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group. Grade 3/4-toxicities normally occurred as individual
incidents. Three women discontinued therapy due to grade
3/4-toxicities. Despite the difference in median age and prior
therapy of the patients, the quantity of observed toxicities
grade 3/4 in this trial is comparable with the toxicities in the
published phase-III trial (Meier et al. 2009).
In another randomized study comparing treosulfan and
carboplatin as monotherapy in older women (median age,
73 years) with advanced ovarian cancer, hematological
toxicities again were comparable to our study, although
patients included into that study had no prior chemotherapy
(Reed et al. 2006). In the treosulfan arm, neutropenia and
leucopenia of grade 3/4 were the most frequently occurring
hematological toxicities, leucopenia being nearly twice as
high as in the carboplatin arm. Leucopenia and neutropenia
also are the most often occurring grade 3/4 hematological
toxicities in our study.
In summary, the observed toxicities were in the same
range as reported in previous studies with significantly
younger patients and less comorbidity or with old women
having received fewer previous lines of chemotherapy.
There were no unexpected hematological or non-
hematological toxicities. Based on this safety analysis,
treosulfan proved to be a safe and tolerable therapeutic
option in elderly, heavily pretreated patients and the next
step of study recruitment was initiated. Of note, the
majority of patients in the interim safety population chose
i.v. treosulfan over the oral application. Detailed analysis
after completion of the trial will hopefully yield new
insight into therapy preference and compliance of elderly
patients with recurrent ovarian cancer.
Conflict of interest The trial was supported by Medac GmbH.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron
W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner
MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG,
Edwards BK (eds) (2010) SEER Cancer Statistics Review,
1975–2007. National Cancer Institute, Bethesda. http://seer.
cancer.gov/csr/1975_2007/, based on November 2009 SEER
data submission, posted to the SEER web site, 2010
Breidenbach M, Rein DT, Scho¨ndorf T, Schmidt T, Ko¨nig E, Valter
M, Kurbacher CM (2003) Hematological side-effect profiles of
individualized chemotherapy regimen for recurrent ovarian
cancer. Anticancer Drugs 14:341–346
Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H
(2007) Trends in population-based cancer survival in Germany;
to what extent does progress reach older patients? Ann Oncol
18:1253–1259
Gropp M, Meier W, Hepp H (1998) Treosulfan as an effective
second-line therapy in ovarian cancer. Gynecol Oncol 71:94–98
Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger
K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J
(2005) Non-enrolment of ovarian cancer patients in clinical
trials: reasons and background. Ann Oncol 16:1801–1805
Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S,
Scheulen ME (2000) Investigation of bioavailability and phar-
macokinetics of treosulfan capsules in patients with relapsed
ovarian cancer. Cancer Chemother Pharmacol 45:483–488
Keldsen N, Madsen EL, Havsteen H, Kamby C, Laursen L, Sandberg
E (1998) Oral treosulfan as second-line treatment in platinum-
resistant ovarian cancer: a phase II study. The Danish Ovarian
Cancer Study Group. Gynecol Oncol 69:100–110
Ko¨pf-Maier P, Sass G (1996) Antitumor activity of treosulfan in
human lung carcinomas. Cancer Chemother Pharmacol
37:211–221
Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter
B, Lu¨ck HJ, Kimmig R, Pfisterer J (2009) Topotecan versus
treosulfan, an alkylating agent, in patients with epithelial ovarian
cancer and relapse within 12 months following 1st-line plati-
num/paclitaxel chemotherapy. A prospectively randomized
phase III trial by the Arbeitsgemeinschaft Gynaekologische
Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gyne-
col Oncol 114:199–205
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia
FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski
J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY,
Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM
(2010) Trabectedin plus pegylated liposomal Doxorubicin in
recurrent ovarian cancer. J Clin Oncol 28(19):3107–3114
Oleitan A, Mocroft A, Jacobs I (2000) Patterns in the incidence of
age-related ovarian cancer in South East England 1967–1996.
BJOG 107:1094–1096
Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring
A, Lacombe D, Monfardini S, Scalliet P, Wildiers H (2010a)
EORTC elderly task force position paper: approach to the older
cancer patient. Eur J Cancer 46:1502–1513
Pallis AG, Wedding U, Lacombe D, Soubeyran P, Wildiers H (2010b)
Questionnaires and instruments for a multidimensional assess-
ment of the older cancer patient: what clinicians need to know?
Eur J Cancer 46:1019–1025
Pignata S, Vermorken JB (2004) Ovarian cancer in the elderly. Crit
Rev Oncol Hematol 49:77–86
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V,
Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S,
Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C,
Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated
liposomal Doxorubicin and Carboplatin compared with Paclit-
axel and Carboplatin for patients with platinum-sensitive ovarian
cancer in late relapse. J Clin Oncol 28(20):3323–3329
Reed NS, Poole CJ, Coleman R, Parkin D, Graham JD, Kaye SB,
Ostrowski J, Duncan I, Paul J, Hay A (2006) A randomised
comparison of treosulfan and carboplatin in patients with ovarian
cancer: a study by the Scottish gynaecological cancer trials
group (SGCTG). Eur J Cancer 42:179–185
Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H,
Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger
W (2008) Nonplatinum topotecan combinations versus topotecan
alone for recurrent ovarian cancer: results of a phase III study of
the North-Eastern German Society of Gynecological Oncology
Ovarian Cancer Study Group. J Clin Oncol 26:3176–3182
Uziely B, Groshen S, Jeffers S, Morris M, Russell C, Roman L,
Muderspach L, Muggia F (1994) Paclitaxel (Taxol) in heavily
pretreated ovarian cancer: antitumor activity and complications.
Ann Oncol 5:8827–8833
J Cancer Res Clin Oncol (2012) 138:1413–1419 1419
123
